Piper Sandler lowered the firm’s price target on AdvanSix (ASIX) to $35 from $39 and keeps an Overweight rating on the shares. The firm cites the release of Q4 2024 and FY2024 earnings results, new 2025 guidance from the company and its own channel checks and estimates for 2025 and 2026. Overall, Piper sees a substantial year-over-year gain in EBITDA for 2025 as AS and acetone continue to contribute strongly to earnings going forward. Nylon, caprolactam and amines, along with other products in the Chemical Intermediates segment, should contribute more modest upside as U.S. and global economic growth remains muted, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASIX:
- AdvanSix Announces Leadership Changes Effective March 2025
- AdvanSix Reports Mixed 2024 Financial Results
- AdvanSix Earnings Call: Mixed Results and Optimistic Outlook
- Morning Movers: Bluebird Bio shares tumble following take-private deal
- Options Volatility and Implied Earnings Moves Today, February 21, 2025
Questions or Comments about the article? Write to editor@tipranks.com